Patients on ovarian cancer drug require ophthalmology follow-up due to corneal toxicity
CHICAGO — Patients treated with mirvetuximab require close follow-up with an ophthalmologist due to the potential for corneal toxicity, according to a study.In a poster presented at the American Academy of Ophthalmology meeting, Filippos Vingopoulos, MD, and colleagues sought to determine how the drug might be affecting the eyes of their patients. Mirvetuximab soravtansine (Elahere,